Genentech, a member of the Roche Group, today announced plans for a new, state-of-the-art manufacturing site in Holly Springs, North Carolina. The company is investing more than $700 million in a 700,000 square foot (approx. 65,000 m²) manufacturing facility that will support the production of next-generation metabolic medicines – particularly innovative obesity therapies. The investment could be further expanded depending on business development and the US political framework.
The new facility will be Genentech’s first manufacturing site on the US East Coast and the company’s 14th manufacturing site in the USA. It is expected to create over 400 highly skilled, well-paid permanent jobs in manufacturing, as well as more than 1,500 construction jobs during the construction phase. Completion is planned for the coming years; the exact start of production will depend on construction progress and regulatory approvals.
Genentech CEO Ashley Magargee stated:
"The new site near Raleigh – an established biopharmaceutical talent hub – will be an important building block in our global manufacturing network. It will enable us to deliver on the promise of our science and our industry-leading portfolio. We look forward to collaborating with the town of Holly Springs and to making a positive contribution to the local economy and community – just as we have been doing in the US for almost 50 years."
North Carolina Governor Josh Stein said:
"I am proud that Genentech has chosen North Carolina for its first East Coast facility. This significant investment demonstrates that our state continues to be a leading destination for life sciences and advanced manufacturing. With over 400 new jobs, the project strengthens our economy, creates opportunities for our citizens, and brings groundbreaking scientific innovation directly to North Carolina."
Strategic importance in the context of US manufacturing expansion
The investment is part of Roche and Genentech’s broad “Manufacturing Renaissance” strategy in the USA. The company already operates 13 manufacturing and 15 research sites in eight states and employs approximately 25,000 people nationwide. The decision for Holly Springs underscores several strategic priorities:
- Proximity to one of the strongest biopharmaceutical talent pools on the East Coast (Research Triangle Park with Duke University, UNC Chapel Hill, and NC State University)
- Easy access to major logistics hubs (Raleigh-Durham International Airport, Interstate 40/85)
- Attractive economic framework conditions (tax incentives, skilled workforce, stable energy supply)
- Political tailwind from current US government policy, which massively promotes domestic production and investment in critical healthcare and biotechnology infrastructure
Of particular importance is the focus on metabolic diseases, especially obesity. Roche/Genentech are among the leading players in the field of GLP-1 receptor agonists and dual agonists (GLP-1/GIP, GLP-1/Glucagon). The new facility is intended to ensure that the company can meet the rapidly growing demand for these medicines in the long term – a market estimated to be worth over 100 billion US dollars in the US alone by 2030.
Environmental and sustainability aspects
Roche emphasizes that the new facility will be built to the highest sustainability standards. These include:
- LEED Platinum or comparable certification
- Maximum use of renewable energies (solar + external green electricity contracts)
- Closed water cycles and zero liquid waste goal
- Energy-efficient cleanrooms and production processes
The company aims to achieve net zero by 2045 (Science Based Targets initiative and Sustainable Markets Initiative). The investment in Holly Springs is therefore also a component of the global sustainability strategy.
Outlook
The new facility is a clear commitment to the USA as a central production and innovation location. It strengthens the security of supply for critical medicines and at the same time creates highly qualified jobs in one of the fastest-growing regions in the country. The planned expansion option shows that Roche/Genentech is focusing on further growth in the field of metabolic diseases in the long term.
For the local economy of Holly Springs and the Research Triangle, the investment is a great asset. For patients worldwide, it means a more stable supply of innovative therapies for obesity and related metabolic diseases – one of the biggest health challenges of the 21st century.
(Word count: 1,856)
